FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1460-1461 May 15, 1997 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Gösta Gahrton and Brian G.M. Durie. 219 pp. London, Arnold, 1996. (Copublished with Oxford University Press, New York.) $89.50. ISBN 0-340-57603-0.

I picked up this book with keen anticipation. Although multiple myeloma is a rare tumor, it is apparently becoming more common, and it is a fascinating paradigm for all cancers. Multiple myeloma introduced us to monoclonality before cloning became fashionable and is encountered in almost every medical specialty. Hematologists and oncologists will claim control, but the tumor invades the practices of immunologists, biochemists, metabolic physicians, nephrologists, and microbiologists, with secondary spread to cardiologists, neurologists, and even orthopedic surgeons.

The book begins well. Kyle's chapter on the history of the disease is a peach — well researched, full of anecdotes, and . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.